0001209191-23-028884.txt : 20230511 0001209191-23-028884.hdr.sgml : 20230511 20230511211353 ACCESSION NUMBER: 0001209191-23-028884 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20230509 FILED AS OF DATE: 20230511 DATE AS OF CHANGE: 20230511 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: SEIDENBERG BETH C CENTRAL INDEX KEY: 0001184592 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-41696 FILM NUMBER: 23912900 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: ACELYRIN, Inc. CENTRAL INDEX KEY: 0001962918 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 852406735 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 4149 LIBERTY CANYON RD. CITY: AGOURA HILLS STATE: CA ZIP: 91301 BUSINESS PHONE: 805-871-4300 MAIL ADDRESS: STREET 1: 4149 LIBERTY CANYON RD. CITY: AGOURA HILLS STATE: CA ZIP: 91301 4 1 doc4.xml FORM 4 SUBMISSION X0407 4 2023-05-09 0 0001962918 ACELYRIN, Inc. SLRN 0001184592 SEIDENBERG BETH C C/O ACELYRIN, INC. 4149 LIBERTY CANYON RD. AGOURA HILLS CA 91301 1 0 1 0 0 Common Stock 2023-05-09 4 C 0 8540729 A 8540729 I See footnote Common Stock 2023-05-09 4 P 0 1250000 18.00 A 9790729 I See footnote Common Stock 2023-05-09 4 P 0 60000 18.00 A 60000 D Series A Redeemable Convertible Preferred Stock 2023-05-09 4 C 0 4056795 D Common Stock 4056795 0 I See footnote Series B Redeemable Convertible Preferred Stock 2023-05-09 4 C 0 2445786 D Common Stock 2445786 0 I See footnote Series C Redeemable Convertible Preferred Stock 2023-05-09 4 C 0 2038148 D Common Stock 2038148 0 I See footnote Director Stock Option (right to buy) 18.00 2023-05-09 4 J 0 23243 0.00 D 2033-05-03 Class A Common Stock 23243 0 D Director Stock Option (right to buy) 18.00 2023-05-09 4 J 0 23243 0.00 A 2033-05-03 Common Stock 23243 23243 D Represents shares of Common Stock received upon conversion of shares of the reported series of preferred stock on a one-for-one basis without payment of further consideration. Shares held directly by Westlake BioPartners Fund II, L.P., or Westlake Fund II. Westlake BioPartners GP II, LLC, or Westlake GP II, is the general partner of Westlake Fund II. Westlake GP II may be deemed to have sole voting and dispositive power with regard to the shares held directly by Westlake Fund II. The Reporting Person and Sean E. Harper are the Managing Directors of Westlake GP II and share voting and dispositive power over the shares held by Westlake Fund II, each of whom disclaims beneficial ownership of the shares held by Westlake Fund II except to the extent of such person's pecuniary interest therein, if any. Represents shares of Common Stock purchased in the Issuer's initial public offering of Common Stock (the "IPO"). Represents shares of Common Stock purchased through a directed share program in the IPO. Each share of preferred stock is convertible into one share of Common Stock and has no expiration date. Immediately prior to the completion of the IPO, all shares of preferred stock automatically converted into shares of Common Stock. Each share of Class A Common Stock was reclassified into one share of Common Stock immediately prior to the completion of the IPO. 1/36 of the shares subject to the option vest on June 4, 2023, and 1/36 of the shares subject to the option vest in equal monthly installments thereafter, subject to the Reporting Person's continued service. /s/ Mina Kim, Attorney-in-fact 2023-05-11